Startups
MiRXES is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses.
We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.
Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers.
We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.
MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.
Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.
We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.
We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.
Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers.
We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.
MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.
Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.
We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.
Overview
Location
Singapore
Employees
201-500
Founded date
2014
Mentions in press and media 19
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 21, 2026 | Hong Kong’s IPO market roars back to life, leading the world in 2025 listings | The Hong Kong Stock Exchange has seen a sharp rise in listing activity over the past year, buoyed by a growing pipeline of applicants and renewed investor interest. The exchange said the city emerged as the world’s top IPO venue in 2025, ov... |
| Jan 21, 2026 | Mirxes to Advance Cancer Screening in Thailand via Strategic N Health Partnership and Launch of At-Home Diagnostic Kits | FITRapid is designed to detect fecal occult blood, an indicator of cancer or polyps in the colon or rectum. Mirxesâ miRNA screening solutions to be deployed across N Healthâs nearly 60 hospitals; Thailand FDA's recent approval of FITRap... |
| Dec 23, 2025 | SE Asia PE market levels up as IPOs, secondaries hit post-pandemic high | Often viewed as “sticky” when it comes to exits, Southeast Asia’s private equity market is showing clearer liquidity outcomes as the post-pandemic reset reinforces valuation discipline and raises execution standards, DealStreetAsia’s Southe... |
| May 28, 2025 | CNBC’s The China Connection newsletter: What chip shortage? 10 questions with AI startup unfazed by U.S.-China tensions | Monday - Friday, 10:00 - 11:00 SIN/HK | 0400 - 05:00 CET After a stint in data science at Meta and neural studies at Caltech, Jerry Ye said that at the behest of an investor, he returned to China in 2017 with the aim of starting a global co... |
| Jan 13, 2025 | CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion | - R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer e... |
| Jul 13, 2024 | IN FOCUS: Singapore’s stock market at ‘rock bottom’. What will it take to shake things up? | Listen to this article IN FOCUS: Singapore's stock market at 'rock bottom'. What will it take to shake things up? 1 min New: You can now listen to articles. This audio is generated by an AI tool. SINGAPORE: Mr S Nallakaruppan recalls 1993 a... |
| Jun 18, 2024 | Thermo Fisher Scientific, National University Hospital and Mirxes Collaborate to Enhance Access to Advanced Genomic Testing for Early Cancer Detection in Singapore | Partnership Aims to Personalize Cancer Care Tailored to the Needs of Southeast Asian Population to Provide Better Individualized Care SINGAPORE, June 18, 2024 /PRNewswire/ -- To increase patient access to affordable, advanced genomic testin... |
| Sep 27, 2023 | Temasek-backed venture builder co-leads $16m round of Automera | InvestmentsNews Miguel Cordon · 27 Sep 2023 · 2 min readTemasek-backed venture builder co-leads $16m round of Automera Photo credit: Shutterstock Automera, a Singapore-based biotechnology company, has raised US$16 million in series A financ... |
| Aug 16, 2023 | Healthcare-focused VC merges with Jungle Ventures | InvestmentsNews Miguel Cordon · 17 Aug 2023 · 1 min readHealthcare-focused VC merges with Jungle Ventures Photo credit: Jungle Ventures HealthXCapital (HXC), an early-stage venture fund based in Singapore, has merged with Jungle Ventures. T... |
Show more
Reviews 0
FAQ about MiRXES
When was MiRXES founded?
MiRXES was founded in 2014.
What has the press written about MiRXES?
Parsers VC has collected 19 articles mentioning MiRXES, among them “Hong Kong’s IPO market roars back to life, leading the world in 2025 listings” (Jan 21, 2026) and “Mirxes to Advance Cancer Screening in Thailand via Strategic N Health Partnership and Launch of At-Home Diagnostic Kits” (Jan 21, 2026).
Is MiRXES still active?
Yes, MiRXES is active; its latest activity on Parsers VC dates from Oct 17, 2026.